Li Auto (02015.HK) launched the updated L8, offered in Ultra and Livis trims with limited-time introductory prices of 359,800 yuan and 419,800 yuan respectively.

Sinovac Biotech’s fully human anti-tetanus monoclonal antibody SNA02-48 injection has entered a Phase III trial, with the first volunteer enrolled at Shenzhen Second People’s Hospital. SNA02-48 was cleared for clinical use in March 2025 and is a recombinant fully human mAb for emergency post-exposure prophylaxis against tetanus. Sinovac is expanding a wound-care portfolio covering active and passive immunity: its adsorbed tetanus vaccine is market-approved; Sinovac-backed Xingmeng Biotech’s Class 1 innovative drug Krebi® (monoclonal antibody injection) is approved for passive immunization of adults exposed to rabies; Sinovac’s lyophilized human rabies vaccine (serum-free Vero cell) is in the regulatory filing stage.

Bank of England MPC member Taylor said in his view holding rates unchanged at this level is the correct and appropriate policy response.